Unadjusted post-recurrence OS was numerically lower with palbociclib plus endocrine therapy vs endocrine therapy alone in the phase 3 PALLAS trial.
Riley Kandel
Advertisement
Articles by Riley Kandel
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel Vaccine Combo Shows Responses in Recurrent Epithelial Ovarian Cancer
2
Firmonertinib Demonstrates Promise in EGFR+ Advanced/Metastatic NSCLC
3
FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer
4
FDA Accepts NDA for Bezuclastinib Combo in Gastrointestinal Stromal Tumors
5